評論
打印
New Cancer Drugs Harness Power of Immune System,The Wall Street Journal,May 15th, 2013
新癌癥藥物使免疫系統變得更強大，華爾街日報，2013年5月15日
In the Bristol-Myers study, using a two-drug combination that targets the immune system resulted in "rapid and deep tumor regressions" in nearly one-third of 52 skin cancer patients treated with the combination, researchers said.
據研究人員說，在Bristol-Myers研究中，用兩種藥物聯合治療免疫系統疾病，導致在52名皮膚癌患者中將近三分之一的人出現顯著的回歸相關性。
The drugs were melanoma treatment Yervoy, already on the market, and the company's experimental drug nivolumab.
治療黑色瘤病的藥物Yervoy,和實驗性藥物nivolumab已經上市。
The combination was more efficient than each drug given alone, said Jedd Wolchok, an oncologist at Memorial Sloan-Kettering Cancer Center in New York, who led that study.
負責這項研究的紐約紀念Sloan-Kettering癌癥中心的腫瘤學家Jedd Wolchok說，藥物聯合治療比單獨治療更有效。
Scientists have been trying for decades to understand why the body's immune system didn't see cancer cells as the enemy and attack them.
為什么身體的免疫系統不能識別癌細胞并攻擊它們，這一問題科學家們已研究了數十年。
Recent discoveries revealed that tumors are adept at cloaking themselves by hijacking the body's own mechanism for preventing the system's T-cells, the infection-and disease-fighting cells of the immune system, from running amok against healthy tissues.
最新研究發現，腫瘤擅長通過劫持身體免疫系統的T細胞、抗感染和抗疾病細胞來隱藏自己，并大肆破壞人體健康。
Though the studies are small, the results reflect rapidly growing conviction that immunotherapy is the next big front in the war on cancer.
盡管研究很小，但研究結果發現了一個快速發展的理念。那就是，免疫療法將是抗癌戰爭中的下一個戰役。
Merck & Co., for instance, is also moving quickly with a candidate that targets the immune system.
比如，默克公司正將其目標轉移到免疫系統的研究上來。
Side effects of the drugs include inflammation associated with the immune system's activation against tumors, but researchers said they were either resolved or were treated without serious consequence.
藥物的副作用包括引發了對抗腫瘤的免疫系統的炎癥，但研究者認為對這一副作用的治療效果不明顯。
Based on the results, Roche is planning to launch a late-stage trial of its PD-L1 inhibitor in lung-cancer patients，while Bristol-Myers is moving its combination regimen into late-phase studies as well.Thank you.
基于研究結果，Roche正計劃在腫瘤患者身上開始一個關于PD-L1抑制劑的后期實驗，Bristol-Myers也將對它的聯合療法進行后一階段的研究。謝謝。
